Oral Abstract Sessions include leading-edge research in HIV, hepatitis viruses, SARS-CoV-2, and other viral infections and their related conditions. During these 2-hour sessions, 8 or 9 speakers have up to 8 minutes (including introductory and acknowledgment slides) to present their research on a specific topic area and respond to questions from attendees in 1 of 2 question-and-answer periods moderated by experts in the field. Moderators introduce presenters and facilitate audience discussion during 2 live question-and-answer periods.
Presenting an Oral Abstract
All oral abstract presenters are required to prepare an 8-minute presentation. An optimal 8-minute presentation has 8 content slides (plus 1 title slide that includes the abstract title, presenting author name, presenting author institution, and financial disclosure).
An optional slide template will be provided to presenters prior to CROI.
Live Question-and-Answer Period
All oral abstract presenters should plan to attend the entire session and participate in the live question-and-answer periods to which they have been assigned. Part 1 of the question-and-answer period will follow the first four presentations and Part 2 will follow the remaining presentations.
Trade names for drugs should not be used in abstracts. Refer to drugs and products by their nonproprietary names.
Statements of Support
Statements of grant support or funding statements may not be included in the abstract text (eg, Study was funded by NIH). Statements of support may be included in the presentation of the abstract at CROI, if accepted.
Sex Stratification and Other Demographic Variables
Abstracts from randomized trials and cohorts should follow the ICMJE guidelines, including reporting of study designs (eg, prospective, observational, randomized, double-blind, STROBE, CONSORT, or others), statistical methods, and outcomes by demographic variables. For human clinical or epidemiological studies, the presentation should provide sex-stratified results or identify who was included if it includes only a single population. Abstracts of preclinical data including the use of cell lines and animal studies should include the sex of the animals or the sex of the source of the cell lines. If data are not available on sex (as assigned at birth) or gender (where gender is relevant to the study results), this should be identified as a limitation in the study.
Use of Appropriate Terminology
It is important to use “people first” language such as “people with HIV” rather than “HIV-infected people.” Similarly, do not characterize people by their conditions. “People with diabetes” is preferred over “diabetics”; “patients with cirrhosis” rather than “cirrhotics;” “people who inject drugs” rather than ‘drug abusers.” Out of respect for their contributions to our scientific advances, avoid calling study volunteers “subjects.” The preferred terms are study “participants” or “volunteers.” Ensure correct use of the terms sex (when reporting biological factors) and gender (identity, psychosocial or cultural factors). Appropriate terminology such as “cisgender” (people whose gender matches the sex assigned at birth) or “transgender” (people whose gender does not match the sex assigned at birth) should be used.
Abstracts Describing New Compounds
Please be sure to include information sufficient to allow for meaningful review of compound data; this can include isolation, activity, chemical structure, mechanism of action, toxic effects, and pharmacologic data. The chemical or molecular structure must be shown in the presentation (it need not be part of the abstract or be published in the abstract eBook).
Case Reports and Systematic Reviews
In general, CROI does not accept abstracts for case reports, meta-analyses, or systematic reviews unless they are of enormous public health significance.
If study data are accepted for publication or presentation after the abstract submission to CROI, and that publication or presentation is expected to take place before CROI, the presenting author must contact CROI at CROIabstracts@iasusa.org to provide details as soon as the presentation is accepted for review, presentation, or publication in another venue or outlet. Please be aware that, although publication in these circumstances will not necessarily prevent presentation of the research at CROI, our strong preference is that any additional publication or presentation happen either simultaneous to or after presentation at CROI. Requests to publish or present research accepted for presentation at CROI prior to its presentation at CROI will be evaluated on a case-by-case basis. Failure to notify the conference promptly regarding plans to publish or present a CROI-accepted abstract prior to CROI may result in the removal of the study from the conference program.